Insights from recent customer interactions with leading pharmaceutical manufacturers
Introduction
This week, we had conversations with QC and R&D leadership from leading biopharma companies across India.
The conversation wasn’t about marketing our products. It was about understanding their analytical challenges in HCP (Host Cell Protein) testing — one of the most critical quality attributes in biosimilar manufacturing.
What we heard was consistent. The same five mistakes appear across teams, institutions, and projects.
And the companies solving these mistakes are the ones implementing deNOVO HCP ELISA kits in their manufacturing workflows.
This article breaks down those 5 mistakes and shows exactly how real biopharma teams are solving them.
Mistake #1:
Using HCP Kits with insufficient sensitivity margins
The Problem
Your product specification says: “HCP ≤ 100 ng/mL (acceptance criterion)”
You choose an ELISA kit with 10 ng/mL LOQ (Limit of Quantitation).
That’s only 10x margin between your sensitivity and your limit.
Regulators expect 10-20x margin.
Why?
Manufacturing variability happens
Batch-to-batch kit inconsistency occurs
Edge cases need buffer
The Solution
Leading biopharma teams are now:
✅ Selecting kits with 2-5x lower LOQ than their specification
(e.g., 2 ng/mL LOQ for 100 ng/mL spec)
✅ Running 3+ independent suppliers’ kits during development (validating consistency)
✅ Building regulatory-ready validation documentation upfront
Our customers implement:
Our E. coli HCP ELISA Kit (1.95-500 ng/mL range, LOQ ~1.95 ng/mL) gives teams the margin they need for stringent specs while maintaining dynamic range for high-concentration batches.
Mistake #2:
Skipping antibody coverage validation for your specific process
The Problem
Generic HCP assays work for “most” E. coli strains.
But your bioreactor uses strain XYZ. Or you’ve optimized fermentation in a unique way. Or your downstream purification introduced unusual selective pressure on which HCPs remain.
Result:
Your HCP ELISA kit doesn’t actually detect 30-40% of the impurities in your process.
Regulators see this during review. RFI (Request for Information) issued. Timeline delayed.
The Solution
Leading biopharma teams are now:
✅ Running Antibody Affinity Extraction (AAE) studies early (week 2-3 of development)
✅ Confirming ≥80% antibody reactivity to their process-specific HCPs
✅ Documenting coverage in regulatory submissions
Mistake #3:
Poor Matrix Recovery Testing
The Problem
Matrix recovery is simple concept: spike known HCP into your actual drug product, measure recovery.
Target: 80-120% recovery (meaning your assay accurately measures HCP in your specific matrix).
What most teams do?
Run recovery in PBS (generic buffer).
What regulators expect?
Recovery in your actual formulation buffer (with all excipients present).
If your formulation has polysorbate, high protein concentration, or unusual pH — that changes recovery. Sometimes dramatically.
The Solution
Leading biopharma teams are now:
✅ Running matrix recovery in ACTUAL drug product formulation (not surrogates)
✅ Testing low, medium, and high HCP concentrations
✅ Repeating across 3+ lots of formulation (to account for batch variability)
✅ Documenting all in regulatory package
Mistake #4:
Import Delays Causing Project Bottlenecks
The Problem
You are ready for analytical method validation. Your HCP kit is stuck in:
Customs clearance (2 weeks)
Cold chain logistics (1 week)
International freight (2 weeks)
Distributor inventory delays (1 week)
Total: 6-8 weeks.
Your project is delayed.
And if the kit doesn’t arrive in time for a regulatory meeting?
That’s a month of lost competitive advantage.
The Solution
Leading biopharma teams are now:
✅ Securing indigenous suppliers as primary (1-2 week delivery) + global suppliers as backup
✅ Building inventory buffers (6+ months supply on hand)
✅ Eliminating import-dependent critical paths
Our customers implement:
Order deNOVO kits → Delivered in 1-2 weeks
Use saved 6-7 weeks for additional validation studies
Pass regulatory review faster
Launch biosimilar months earlier
Mistake #5:
No Technical Support when assays fail
The Problem
Your HCP ELISA isn’t working as expected:
Recovery is low in one buffer but not others
Background is high with certain samples
Sensitivity dropped between lots
You email your vendor. 24-hour response time (if you’re lucky).
Generic troubleshooting via email.
No deep dive into your specific assay conditions.
Meanwhile, your validation is frozen.
The Solution
Leading biopharma teams are now:
✅ Partnering with suppliers who offer on-site technical support
✅ Having direct scientist-to-scientist conversations (not sales reps)
✅ Getting protocol customization for their specific needs
What do Biopharma Companies do differently?
When we spoke with QC and R&D leadership this week, we identified a clear pattern:
Companies implementing deNOVO HCP ELISA kits are:
1. Choosing sensitivity wisely (not just the cheapest option)
2. Validating antibody coverage early (saving 6-12 weeks later)
3. Testing in actual matrices (not generic buffers)
4. Eliminating import delays (securing 1-2 week indigenous supply)
5. Building technical partnerships (not just vendor relationships)
And the result?
Faster validation timelines. Regulatory confidence. Successful manufacturing implementation.
Customer Feedback
This is the validation we are most excited about:
Multiple biopharma customers have confirmed on-par performance with their incumbent (imported) HCP ELISA kits. And critically, they’re planning to implement deNOVO kits in their actual manufacturing workflows.
What that means:
-Batch release testing uses deNOVO kits
-Quality control relies on deNOVO reagents
-Manufacturing documentation references deNOVO protocols
-Long-term procurement contracts include deNOVO
What’s Next?
Beyond the companies already implementing deNOVO, we’re seeing another cohort: customers excited to evaluate Make in India products in their workflows.
These are companies that:
> Want to reduce import dependency
> Seek local supply chain resilience
> Need faster troubleshooting support
If this sounds like your organization, here’s what to do
Step 1: Free Evaluation
Request free sample evaluation of our E. coli HCP ELISA Kit:
– We’ll test your specific process HCP
– Show comparative performance vs your current kit
– Provide application support for matrix optimization
Step 2: Matrix Validation
If results look promising:
– Conduct formal matrix recovery validation in your formulation
– Validate across your process conditions
– Build regulatory documentation together
Step 3: Manufacturing Workflow Implementation
Transition to deNOVO kits for:
– Development batch testing
– Pilot manufacturing
– Full production release
If you’re developing biosimilars and struggling with HCP testing:
📧 Email us: info@denovobiolabs.com
📞 Call: +91 80 29575711